KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Common Equity: 2009-2025

Historic Common Equity for Novavax (NVAX) over the last 14 years, with Sep 2025 value amounting to -$156.7 million.

  • Novavax's Common Equity rose 70.24% to -$156.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$156.7 million, marking a year-over-year increase of 70.24%. This contributed to the annual value of -$623.8 million for FY2024, which is 12.98% up from last year.
  • Novavax's Common Equity amounted to -$156.7 million in Q3 2025, which was down 516.40% from $37.6 million recorded in Q2 2025.
  • Over the past 5 years, Novavax's Common Equity peaked at $1.0 billion during Q1 2021, and registered a low of -$895.6 million during Q1 2023.
  • Its 3-year average for Common Equity is -$517.2 million, with a median of -$623.8 million in 2024.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 4,434.93% in 2021, then slumped by 1,470.98% in 2023.
  • Over the past 5 years, Novavax's Common Equity (Quarterly) stood at -$351.7 million in 2021, then crashed by 80.30% to -$634.1 million in 2022, then fell by 13.07% to -$716.9 million in 2023, then grew by 12.98% to -$623.8 million in 2024, then skyrocketed by 70.24% to -$156.7 million in 2025.
  • Its Common Equity stands at -$156.7 million for Q3 2025, versus $37.6 million for Q2 2025 and -$75.6 million for Q1 2025.